natgillin/translations-raw huggingface dataset:
A fragment of full-length FliD is a fragment the amino acid sequence of which is shorter than the amino acid sequence of full-length FliD, whereby the fragment of FliD is still active as a virulence factor. 
Uporaba sukladno zahtjevu 7, naznačena time, da komplet sadrži FliD puno duljine ili njegov e fragment, pri čemu je fragment fragment čija je aminokiselinska sekvenca kraća od aminokiselinske sekvence pune duljine FiD, pri čemu je fragment još uvijek aktivan kao čimbenik virulencije.
A toothbrush (10) according to claim 5 characterized in that the triangle is equilateral or isosceles. 
Četkica za zube (10), u skladu s patentnim zahtjevom 5 naznačena time što trokut je ekvilateralan ili istokračan.
a central through-bore 178 for fastening by means of a central screw 174 to the bottom 136 of the first cup-shaped body portion 130 below the inlet port 137 for the admission of the water required to prepare the beverage; 
središnji provrt 178 za pričvršćivanje središnjim vijkom 174 na dno 136 prvog trupa u 1 obliku šalice 130 ispod ulaznog priključka 137 za ulaz vode potrebne za pripravljanje napitka;
Methods of making and separating stereoisomers are known in the art. 
odvajanje stereoizomera su poznati u tehnici. a.
An epoxy compound or a salt thereof, represented by the general formula (2): wherein R1 represents hydrogen or a lower alkyl group; 
HR P20120091 T1 HR P20120091 T1 PATENTNI ZAHTJEVI 1. -Epoksi spoj ili njegova sol, prikazan općom formulom (2):
More preferably, the linker L′ is selected from the group consisting of hexaethyleneglycol, tetradeoxythymidylate (T4) and 2,19-bis(phosphor)-8-hydraza-1-hydroxy-4-oxa-9-oxo-nonadecane; and m is 1 and L is a carboxamido polyethylene glycol, preferably a carboxamido triethylene glycol; and C is selected from the group consisting of single or double chain fatty acids, folates and cholesterol. More preferably, C is selected from the group consisting of dioleoyl, octadecyl, folic acid, and cholesterol. 
(Ile), gdje se podcrtani nukleotid odnosi na nukleotid koji ima ili koji nema fosforotioatnu ili metilfosfonatnu okosnicu, vezani L' se bira iz skupine koju čine heksaetilen-glikol, tetradeoksitimidilat (T4) 1 2,19-bis(fosfor)-8-hidraza-1- hidroksi-4-oksa-9-oksononadekan; m je 1, L je karboksamidooligoetilen-glikol, a C se bira iz skupine koju čine dioleo1l, oktadecil, folna kiselina, tokoferol i kolesterol.
Medicament combinations which contain, besides one or more compounds of a compound according to anyone of claims 1 to 16, as further active substances, one or more compounds selected from among the categories of further ENaC inhibitors, betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, dopamine agonists, H1-antihistamines, PAF-antagonists, MAP-kinase inhibitors, MPR4-Inhibitors, iNOS-lnhibitors, SYK-Inhibitors, corrections of the cystic fibrosis transmembrane regulator (CFTR) and CFTR potentiators or double or triple combinations thereof. 
Kombinacije lijekova, naznačene time, da osim jednog ili više spojeva od spoja prema bilo kojem od zahtjeva 1 do 16, kao dodatne djelotvorne tvari, obuhvaćaju jedan 1li više spojeva odabranih između sljedećih kategorija: ENaC-inhibitori, betamimetici, antiholinergici, kortikosteroidi, PDE4-inhibitori, LTD4-antagonisti, EGFR- inhibitori, dopaminski agonisti, H1-antihistamini, PAF-antagonisti, inhibitori MAP-kinaze, MPR4-Inhibitori, iNOS-inhibitori, SYK-inhibitori, korektivi transmembranskih regulatora cistične fibroze (CFTR) i CFTR- pojačivači, 1li dvostruke ili trostruke kombinacije od navedenih.
In other aspects, the antibody of the present invention is a composition comprising the isolated antibody or antigen-binding portion thereof of claim 1 and a pharmaceutically acceptable carrier. 
- Supstancija koja sadrži izolirano antitijelo, dio koji veže antigen ili fragment antitijela koji veže epitop na ljudski CADMI sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2 i farmaceutski prihvatljivog nosača.
The compound of claim 2 wherein R1 is (C2-C4)alkyl; A1 and A2 are each independently phenyl, pyrazolyl, imidazolyl, triazolyl, pyridinyl, pyrimidinyl, indolyl, benzopyrazinyl, benzoimidazolyl, benzoimidazolonyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, indazolyl, indolinonyl, naphthyridinyl, quinolinyl, quinolinonyl, dihydroquinolinonyl, oxo-dihydroquinolinonyl, isoquinolinyl, isoquinolinonyl, dihydroisoquinonyl or oxo-dihydroisoquinonyl, wherein each A1 and A2 are optionally substituted with one to three substituents independently selected from fluoro, chloro, methyl, methoxy, amino, methylamino, dimethylamino, amido or cyano; or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 2, naznačen time što je R1 (C2-C4)alkil; svaki od A1 i A2 je neovisno fenil, pirazolil, imidazolil, triazolil, piridinil, pirimidinil, indolil, benzopirazinil, benzoimidazolil, benzoimidazolonil, pirolopiridinil, pirolopirimidinil, pirazolopiridinil, pirazolopirimidinil, indazolil, indolinonil, naftiridinil, kinolinil, kinolinonil, dihidrokinolinonil, oksodihidrokinolinonil, izokinolinil, izokinolinonil, dihidroizokinonil ili oksodihidroizokinonil, gdje svaki od A1 i A2 može biti supstituiran s jednim do tri supstituenta, koje se neovisno bira između fluora, klora, metila, metoksi, amino, metilamino, dimetilamino, amido ili cijano; ili njegova farmaceutski prihvatljiva sol.
Use of claim 29, wherein the administration is made in form of liposomes. 
Uporaba prema patentnom zahtjevu 30, naznačena time što se primjena izvodi u obliku lipozoma.
The composition of claim 3 wherein said copper salt is selected from the group consisting of copper carbonate, copper nitrate, copper sulfate, copper chloride, and combinations thereof. 
Sastav prema zahtjevu 3, naznačen time da je sol bakra odabrana iz skupine koja se sastoji iz bakar-karbonata, bakar-nitrata, bakar-sulfata, bakar-klorida i njihovih kombinacija.
a first delivery opening (21) arranged at the upper end of the casing (2), 
navedeni ulazni otvor (11) smješten je na donjem kraju kućišta (2), -
In one embodiment, the invention relates to a polynucleotide comprising a nucleotide sequence encoding an antibody, particularly a monoclonal antibody including any functionally equivalent antibody or functional parts thereof according to the present invention and as described herein wherein said antibody comprises a light chain and a heavy chain variable domain exhibiting an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequences given SEQ ID NO: 17 and SEQ ID NO: 19 and in SEQ ID NO: 18 and SEQ ID NO: 20, respectively, or a functional part thereof comprising the light chain and the heavy chain CDRs as depicted in SEQ ID NOs: 21-26. 
Monoklonsko protutijelo, ili njegov funkcionalni dio, koje prepoznaje i veže se na B-amiloidni protein, te sadrži CDRI lakog lanca s aminokiselinskim slijedom SEQ ID NO: 9; CDR2 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 10; CDR3 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 11; CDRI teškog lanca s aminokiselinskim slijedom SEQ ID NO: 12; CDRI teškog lanca s aminokiselinskim slijedom SEQ ID NO: 13;1 CDR3 teškog lanca s aminokiselinskim slijedom SEQ ID NO: 14, naznačeno time što je namijenjeno upotrebi u sprječavanju, liječenju ili ublažavanju posljedica glaukoma, optičkog neuritisa ili retikularne distrofije. Protutijelo, ili njegov funkcionalni dio, u skladu s patentnim zahtjevom 4, naznačeno time što je namijenjeno upotrebi u liječenju u skladu s patentnim zahtjevom 4 namijenjenom smanjivanju opterećenja plakovima u sloju ganglijskih stanica u mrežnici kod subjekta koji boluje od glaukoma, optičkog neuritisa ili retikularne distrofije.
reacting Compound 25 with Compound 6: to produce Compound 22: and cyclizing Compound 22 to produce Compound 21, wherein X is selected from the group consisting of S, O, and NH. 
[image] kako bi se dobilo Spoj 22: [image] i ciklizaciji Spoja 22 kako bi se dobilo Spoj 21, gdje X se bira iz skupine koju čine S, O i NH.
The method of claim 9, wherein the binding agent is present in an amount ranging from 0.01 wt% to 50 wt% of the formulation. 
Postupak prema zahtjevu 9, naznačen time da je sredstvo za vezanje prisutno u količini od 0,01 mas.% do 50 mas.% formulacije.
aluminium alkyl chlorides having general formula (V): 
- aluminijev alk1l klorid opće formule (V):
The eye disorder is preferably selected from the group of allergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after intraocular lens implantation, inflammation of the optic nerve (neuritis nervi optici), keratitis, dry eye syndrome (keratitis sicca), uveitis, glaucoma, retinal oedema, retinitis pigmentosa and diabetic retinopathy. 
Očni poremećaj je u povoljnom slučaju izabran iz skupine koju čine alergijski konjuktivitis, konjuktivitis uzrokovan bakterijama, virusima ili gljivicama, upalna stanja nakon intraokularne implatacije leće, upala očnog živca (neuritis nervi optici), keratitis, sindrom suhog oka (keatitis sicca), uveitis, glaukom, retinalni edem, retinitis pigmentosa i dijabetička retinopatija.
An annular disk 17 as a first member of an apparatus 11 for fabricating the corresponding container 10 is then positioned inside the cup body 12 and snugly engages the inner surface of the cup wall 22 above the upper shoulder 32, see for example Figures 6 to 8 . 
Prstenasti disk 17, kao prvi element odgovarajućeg uređaja 11 za proizvodnju predmetnog spremnika 10, se tada stavi u tijelo čaše 22 i on čvrsto zahvati unutarnju površinu tijela čaše iznad gornjeg izbočenja 32, vidi, na primjer, slike 6 do 8.
A pharmaceutical composition comprising a compound of any one of clauses 37-47, and a pharmaceutically acceptable excipient. 
20. Farmaceutski sastav koji sadrži spoj prema bilo kojem od zahtjeva 1-19, i farmaceutski prihvatljivu pomoćnu tvar.
The formulation of claim 1, wherein the irbesartan hydrochloride has an average particle size of less than 250 µm. 
Formulacija u skladu sa zahtjevom 1, naznačena time, da irbesartan hidroklorid ima prosječnu veličinu čestice manju od 250 um.
in the presence of a suitable catalyst, a suitable solvent and a suitable base, 
: Het-R) u prisutnosti pogodnog katalizatora, pogodnog otapala i pogodne baze,
In one embodiment, the average particle size (D50), as measured by laser diffraction, was determined to be controllable in the range of 3-30 microns. 
Prekursor materijal prema zahtjevu 1, u kome prekursor materijal ima prosječnu veličinu čestica (D50) u rasponu od 3 do 30 mikrona.
The method of any of claims 6 to 8, further comprising: 
Metoda od 6. do 8. patentnog zahtjeva koja se nadalje sastoji od:
The design of the present invention makes it possible both to introduce the flushing liquid and to take the sample. 
Izvedba predmetnog izuma omogućava oboje, i uvođenje tekućine za ispiranje 1 uzimanje uzorka.
The composition of claim 7, wherein the adjuvant comprises alum. 
Sastav 1z patentnog zahtjeva 7, pri čemu adjuvans sadrži alaun.
The dry sinsemilla cannabis inflorescence of any one of claims 1-6, wherein the first or second most abundant terpene in the terpene profile is selected from the group consisting of limonene, alpha humulene, and beta caryophyllene. 
Suha inflorescencija besjemenog kanabisa u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što se prvi ili drugi najobilatiji terpen u terpenskom profilu bira iz skupine koju čine terpinolen, a-pinen, limonen, te fB-kariofilen.
Accordingly, a compound of the present invention can be used to treat a disease or disorder arising from abnormal cell growth, function or behaviour. Such abnormal cell growth, function or behaviour is typically associated with PI3 kinase. 
Spoj kako se definira u patentnom zahtjevu 1, naznačen time, da je taj spoj namijenjen liječenju bolesti ili poremećaja koji su posljedica abnormalnog rasta stanica, funkcija ili ponašanja povezanih s PI3 kinazom.
Preferentially such a vector is an expression vector suitable for expression (e.g. E. coli, phagemid, or mammalian vectors) and the constant region heavy chain encoding sequences are chosen from the human immunoglobulin classes IgGI, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, or IgE, thereby enabling the expression of a Fab or full-length recombinant antibody. In addition to the constant heavy chain encoding sequences the vector may also contain a constant light chain encoding sequence chosen from human lambda or kappa chains. 
Postupak u skladu s patentnim zahtjevom 15, naznačen time što se dodatno sastoji u prebacivanju navedenog srodnog para ili biblioteke ciljno specifičnih srodnih parova sljedova koji kodiraju varijabilno područje u sisavački ekspresijski vektor, gdje navedeni sisavački ekspresijski vektor izborno kodira jednu ili više domena konstantnog područja, koje se bira između klasa ljudskih imunoglobulina IgA 1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, IgM, lakog lanca kapa ili lakog lanca lambda. HR P20110686 T1 mCHrev1 MVH sklop
(ssss) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO:2, a CDR2 comprising the amino acid sequence of SEQ ID NO:3, and a CDR3 comprising the amino acid sequence of SEQ ID NO:4, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:6, a CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a CDR3 comprising the amino acid sequence of SEQ ID NO:73, 
Izolirano protutijelo monoklonske anti-odbojne vodljive molekule (RGMa) koje sadrži varijabilnu regiju teškog lanca koja sadrži regiju koja određuje komplementarnost (CDR) koja sadrži sekvencu aminokiseline SEQ ID NO:2, CDR2 koja sadrži sekvencu aminokiseline SEQ ID NO:3, i CDR3 koja sadrži sekvencu aminokiseline SEQ ID NO:4, i varijabilnu regiju laganog lanca koja sadrži CDRI1 koja sadrži sekvencu aminokiseline SEQ ID NO:6, CDR2 koja sadrži sekvencu aminokiseline SEQ ID NO:7, i CDR3 koja sadrži sekvencu aminokiseline SEQ ID NO:8 ili SEQ ID NO:73.
The formulation according to (1) to (13), which is stable at 22-28° C. for at least 6 months. 
Formulacija prema zahtjevu 10 ili 11, naznačena time da je stabilna kod 22-28"C tijekom najmanje 6 mjeseci.
A method of treating conditions or diseases selected from Alzheimer's Disease, Lewy body dementia, fronto-temporal dementia, taupathies, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's Disease and parkinsonian syndromes, Huntington's disease, Charcot-Marie-Tooth disease; head trauma, cerebral ischemia, meningitis, cognitive psychiatric disorders; sleep disorders; neuropathic and inflammatory pain, chronic pain, migraine, multiple sclerosis pain, HIV-related neuropathy, HIV-induced neuroinflammation and CNS damage, epilepsy and status epilepticus, inflammatory processes of the musculoskeletal system, liver fibrosis, gastrointestinal tract disorders genito-urinary tract disorders, ophthalmic diseases, chronic obstructive pulmonary disease (COPD), autoimmune diseases nephritis, in a mammal in need thereof: 
Spoj formule (I) prema patentnim zahtjevima 1-7 za upotrebu u sprječavanju i/ili liječenju neurodegenerativnih, kognitivnih, psihijatrijskih poremećaja, neoropatske boli, kronične boli, neuroinflamacije izazvane HIV-om te oštećenja CNS, epilepsije, upalnih procesa mišićno-koštanog sustava, fibroze jetre, poremećaja gastrointestinalnog trakta, poremećaja genito-urinarnog trakta, oftalmičnih bolesti, kronične opstruktivne plućne bolesti (COPD), karcinoma i proliferativnih bolesti.
The compound according to claim 11 or a pharmacologically acceptable salt thereof, or a solvate or hydrate thereof, wherein in the formula (I), Ar2 is a group selected from the group consisting of A1b), A2b), and A7c): 
Spoj u skladu sa patentnim zahtjevom 11 ili njegova farmakološki prihvatljiva sol, ili njegov solvat ili hidrat, gdje u formuli (1), Ar" je grupa odabrana iz grupe koja se sastoji od A1b), A2b), i A7c):
represents a hydrogen atom, a methyl group, an ethyl group, an isopropyl group or a hexyl group, 
R' predstavlja atom vodika, metil skupinu, etil skupinu, izopropil skupinu ili heksil skupinu,
The pharmaceutical composition of any one of the above (30.)-(35.), further comprising a stabilizing agent. 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3-6, gdje farmaceutska kompozicija ima pH od oko 4.
The composition of claim 18, wherein the additional active agent is praziquantel. The composition of any preceding claim, wherein the composition is an oral formulation, a topical formulation or an injectable formulation. 
Veterinarski ili agrikulturni sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da je sastav odabran od oralne formulacije, injektibilne formulacije, topikalne formulacije, dermalne formulacije i subdermalne formulacije.
A humanised antibody having binding specificity for both CD45RO and CD45RB comprising a heavy chain variable region of SEQ ID NO: 31 or 32 and a light chain variable region of SEQ ID NO: 7 or SEQ ID NO: 8. 
Humanizirano antitijelo, naznačeno time, da ima specifičnost vezanja za oba CD45RO i CD45RB sadržavajući varijabilno područje jakog lanca od SEQ ID NO: 31 ili 32 i varijabilno područje slabog lanca od SEQ ID NO: 7 ili SEQ ID NO: 8.
Attempts have been made to develop treatments for HD and one study by Karpuj et al in Nature Medicine, February 2002, vol.8, no.2, pp. 143 -149 has involved the administration of cystamine. 
Bilo je pokušaja da se razvije liječenje za HD i jedna studija Karpuj-a 1 suradnika u Nature Medicine, February 2002, vol.8, no.2, pp.
The method of claim 5, wherein the randomizing codons are selected from the group NNS and NNK, such as wherein the randomizing codons are incorporated at positions encoding at least one loop region selected from the group consisting of residues at or about positions 13-16, 22-28, 38-43, 51-54, 60-64, and 75-81 of SEQ ID NO: 142, 143 and 147-151. 
Metoda iz patentnog zahtjeva 5, pri čemu su nasumični kodoni izabrani iz grupe NNS i NNK, tako da su nasumični kodoni uvršteni na pozicijama kodiranja najmanje jedne regije petlje izabranih iz grupe koja se sastoji od ostataka u/ ili oko pozicija 13-16, 22-28, 38-43, 51-54, 60-64, i 75-81 od SEQ ID BR: 142, 143 i 147-151.
Letermovir according to claim 1, wherein said process for preparing the amorphous Letermovir further comprises dry granulation processing of the amorphous Letermovir subsequent to the isolating. 
Letermovir prema bilo kojem od zahtjeva 1 do 3, pri čemu je dobiveni Letermovir procesiran suhom granulacijom.
A method according to claim 3 or claim 4 further comprising applying a third layer of polymeric material over the second layer, the polymeric material in the third layer being foamed. 
Postupak sukladno patentnom zahtjevu 3 ili patentnom zahtjevu 4 nadalje obuhvaća nanošenje trećeg sloja polimernog materijala preko drugog sloja, polimerni materijal u trećem je sloju pjenast.
The term “C2-6 alkenyl” as used herein refers to a straight or branched chain alkenyl moiety having from 2 to 6 carbon atoms and at least one double bond of either E or Z stereochemistry where applicable. 
Pojam "C2.4-alkenil" kako se ovdje rabi znači ravan ili razgranat lanac alkenilne skupine koja ima od 2 do 6 ugljikovih atoma i najmanje jednu dvostruku vezu s E ili Z stereokemijom, tamo gdje se može primijeniti.
Dissolution is visually checked before continuing, and dissolution is considered complete when it is so appreciated visually The pH of the solution is checked and adjusted to a value in the range from about 1 to about 5, more preferably in the range from about 2 to about 4.5, even more preferably in the rane from about 3 to about 4.5, and most preferably to a pH of about 4.0 by slow addition of a suitable acid. 
Otapanje je vizualno provjereno prije nastavka, i otapanje je uzeto kao završeno kada je to vizualno tako procijenjeno. pH vrijednost otopine provjerena je i podešena do vrijednosti u opsegu od oko 1 do oko 5, poželjnije u opsegu od oko 2 do oko 4 5, čak poželjnije u opsegu od oko 3 do oko 4.5, a najpoželjnije do pH vrijednosti od oko 4.0 laganim dodavanjem pogodne kiseline.
The pharmaceutical composition according to claim 17 for treating or diagnosing a VAP-1 mediated inflammatory disorder selected from the group consisting of arthritides and connective tissue diseases, inflammatory bowel diseases, dermatoses, multiple sclerosis, inflammatory neuropathy, inflammatory myopathy, acute disseminated encephalomyelitis, vasculitis of the central nervous system, Sjögrens syndrome, diabetes, systemic lupus erythematosus, asthma, inflammatory liver disease, Graves disease and thyroiditis. 
Farmaceutski pripravak prema zahtjevu 17 za uporabu u liječenju ili dijagnostici VAP-1 posredovanog upalnog poremećaja izabranog iz skupine koja se sastoji od artritisa i bolesti vezivnog tkiva, upalnih bolesti crijeva, dermatoze, multiple skleroze, upalne neuropatije, upalne miopatije, akutnog diseminiranog encefalomijelitisa, vaskulitisa središnjeg živčanog sustava, Sjögrenovog sindroma, dijabetesa, sustavnog eritemskog lupusa, astme, upalne bolesti jetre, Gravesove bolesti i tiroiditisa.
By means of said device, the processes according to the invention can be realized in a particularly simple and fast manner in order to achieve the advantages which are discussed above. 
Pomoću navedenog uređaja može se postupak koji je u skladu s ovim izumom ostvariti na naročito jednostavan i brz način, da bi se pri tome postigle prednosti o kojima se gore raspravlja.
The organic phase is dried (Na2SO4), filtered, and concentrated in vacuo to yield 8.5 g, which is used without further purification. 
Organsku fazu se osuši (Na,SOy), filtrira, te koncentrira u vakuumu kako bi se dobilo 8,5 g spoja, kojeg se upotrebljava bez daljnjeg pročišćavanja.
a VL chain with at least 95%, 96%, 97%, 98 or 99% identity to the amino acid sequence set forth in SEQ ID NO: 170, wherein the VL comprises no more than one amino acid substitution within the CDRs relative to the VL CDR1 amino acid sequence set forth in SEQ ID NO: 179, the VL CDR2 amino acid sequence set forth in SEQ ID NO: 181, and the VL CDR3 amino acid sequence set forth in SEQ ID NO:183; or 
VL lanac sa najmanje 95%, 96%, 97%, 98 ili 99% identičnosti sa amino kiselinskom sekvencom navedenom u SEQ ID NO: 206, gdje VL sadrži ne više od jedne amino kiselinske supstitucije unutar CDR regiona u odnosu na VL CDR1 amino kiselinsku sekvencu navedenu u SEQ ID NO: 215, VL CDR2 amino kiselinsku sekvencu navedenu u SEQ ID NO: 217, i VL CDR3 amino kiselinsku sekvencu navedenu u SEQ ID NO:219; ili
The compound for use according to claim 1, wherein tipifarnib is administered for a period of one to seven days. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu je tipifarnib primjenjivan u razdoblju od jednog do sedam dana.
In other cases, suitable heating conductors form surfaces comprising heating conductors and their supply lines. 
U drugim slučajevima prikladni vodiči koji se zagrijavaju čine površine koje sadržavaju vodiče koji se zagrijavaju i njihove vodove za napajanje.
The resulting suspension is collected by filtration and dried in vacuo at 50 °C to yield a solid which is purified by recrystallisation from IPA/water (1:3) to afford the titled product. 
Dobivenu suspenziju se skupi filtracijom i osuši u vakuumu pri 50%, čime se dobije krutinu koju se očisti prekristalizacijom iz IPA/vode (1:3), čime se dobije naslovni proizvod.